Back to top
more

Illumina (ILMN)

(Real Time Quote from BATS)

$135.66 USD

135.66
708,144

-3.36 (-2.42%)

Updated Oct 3, 2024 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacific Biosciences Introduces Enhancements to Sequel System

by Zacks Equity Research

The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.

    Illumina (ILMN) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    Illumina (ILMN) closed the most recent trading day at $328.96, moving +0.73% from the previous trading session.

    Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?

    by Zacks Equity Research

    Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.

    Illumina (ILMN) Q3 Earnings Preview: What's in the Cards?

    by Zacks Equity Research

    Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Illumina (ILMN) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    Illumina (ILMN) closed the most recent trading day at $307.45, moving +0.88% from the previous trading session.

    Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

    by Zacks Equity Research

    Sector ETF report for PBE

    Why Illumina (ILMN) Could Beat Earnings Estimates Again

    by Zacks Equity Research

    Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

      Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce

      by Zacks Equity Research

      Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).

        Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM

        by Zacks Equity Research

        Zacks.com highlights: Illumina, Weight Watchers International, Inogen, Caterpillar and QUALCOMM

          Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?

          by Zacks Equity Research

          Is (ILMN) Outperforming Other Medical Stocks This Year?

            Sanghamitra Saha headshot

            Looking for Earnings Beat? Play These Top 5 Stocks

            by Sanghamitra Saha

            These top-ranked stocks may surpass bottom-line estimates in their next release.

              Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher

              by Zacks Equity Research

              Atara Biotherapeutics (ATRA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

                Alexion's Soliris Successful in Phase III Study for NMOSD

                by Zacks Equity Research

                Alexion's (ALXN) efforts to expand lead blockbuster drug Soliris' label gets a boost as the phase III study on the drug for the indication of NMSOD was successful.

                  AnaptysBio (ANAB) Looks Good: Stock Adds 9.9% in Session

                  by Zacks Equity Research

                  AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

                    Is First Trust Multi Cap Growth AlphaDEX Fund (FAD) a Hot ETF Right Now?

                    by Zacks Equity Research

                    Smart Beta ETF report for FAD

                      Nalak Das headshot

                      Major Stock Indexes Approaching Record Highs: 5 Top Picks

                      by Nalak Das

                      The three major stock market indexes ??? the Dow 30, S&P 500 and Nasdaq Composite ??? are at present within the striking distance to achieve their all-time high level.

                        Cytori's Chemotherapy Candidate Gets Orphan Drug Status

                        by Zacks Equity Research

                        Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.

                          AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology

                          by Zacks Equity Research

                          AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.

                            The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

                            by Zacks Equity Research

                            The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

                              DENTSPLY Launches Azento, Improves Digital Implant Workflow

                              by Zacks Equity Research

                              DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.

                                Nitish Marwah headshot

                                IPOs and Foreign Investment Propel Biotech: 4 Top Picks

                                by Nitish Marwah

                                A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.

                                  Nabaparna Bhattacharya headshot

                                  Allscripts' Sunrise Abstracting Selected by Wyckoff Heights

                                  by Nabaparna Bhattacharya

                                  Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.

                                    Is Illumina (ILMN) Stock Outpacing Its Medical Peers This Year?

                                    by Zacks Equity Research

                                    Is (ILMN) Outperforming Other Medical Stocks This Year?

                                      Sweta Killa headshot

                                      Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

                                      by Sweta Killa

                                      Sector ETF report for ARKG

                                        Here's Why You Should Hold On to DaVita (DVA) Stock Now

                                        by Zacks Equity Research

                                        Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.